
Once back home, attendees will not have a load of practice-changing studies in their suitcase. They will rather have updated and checked their knowledge of recent evidence and best current practice in the field of lung cancer.
Looking back at the major advances in recent years – in particular due to advances in genetic profiling, imaging, and last but not least: immunotherapy – keeping up is an ever bigger challenge. Helping you to keep up is also our aim, providing you in this Medicom Report with some major summaries of ELCC events (acknowledging in advance that it cannot reflect the totality of the conference).
Wishing you an interesting and educating read,
Yours, sincerely,
Stefan Rauh
Biography
Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is Chair of the ESMO Practicing Oncologist’s Working Group since 2015, member of the ESMO Quality Task Force, extended member of the ESMO Public Policy Committee, Assistant Editor of ESMO Cancer Horizons, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.
Conflict of Interest:
Nothing to disclose.
Posted on
Previous Article
« Post-study immunotherapy in MYSTIC Next Article
Experiences from France »
« Post-study immunotherapy in MYSTIC Next Article
Experiences from France »
Table of Contents: ELCC 2019
Featured articles
Electromagnetic navigation bronchoscopy
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Electromagnetic navigation bronchoscopy
Genomic and immune profiling
Immunotherapy in Stage 4 Lung Cancer
Other I-O combinations
Predictive diagnostics for I-O
Trials: Immunotherapy in Stage 4 Lung Cancer
Post-study immunotherapy in MYSTIC
Implementation of Personalised Lung Cancer Care in Clinical Routine
How can societies help to implement personalised treatment?
Optimal Management of Brain Metastases in NSCLC
Incidence and local treatment
Brain irradiation as treatment option
Small Cell Lung Cancer: New Targets
Molecular characteristics of SCLC
Immunotherapy in SCLC: trial data
Related Articles
September 21, 2020
AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain

November 25, 2020
Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com